Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
3SBio ( (HK:1530) ) has issued an update.
3SBio reported a sharp acceleration in growth for the year ended 31 December 2025, with revenue almost doubling to RMB17.70 billion and gross profit climbing 108.8% to RMB16.35 billion, supporting a gross margin of 92.4%. Net profit attributable to shareholders surged 305.8% to RMB8.48 billion, while adjusted net profit and adjusted EBITDA also posted substantial triple-digit gains, reflecting strong underlying operations despite non-operating items.
The Board maintained a stable shareholder returns policy by proposing a final dividend of HKD0.25 per share, unchanged from the prior year, signaling confidence in the company’s cash generation and balance-sheet strength. The combination of rapid top-line expansion, significantly higher earnings, and a steady dividend payout underscores 3SBio’s strengthened financial position and may bolster its competitive standing in the regional biopharma market.
The most recent analyst rating on (HK:1530) stock is a Hold with a HK$25.00 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.
More about 3SBio
3SBio Inc., incorporated in the Cayman Islands and listed in Hong Kong, operates in the biopharmaceutical sector. The company focuses on developing and commercializing pharmaceutical products in China and related markets, with revenue and profitability primarily driven by its portfolio of specialty therapies and biologics.
YTD Price Performance: -0.83%
Average Trading Volume: 23,046,124
Technical Sentiment Signal: Buy
Current Market Cap: HK$60.86B
See more data about 1530 stock on TipRanks’ Stock Analysis page.